Browse a selection of ImaginAb press and news below.
ImaginAb Announces Publication of Data on First-In-Human Imaging in Patients with Solid Malignancies in The Journal of Nuclear Medicine
ImaginAb Inc., a clinical-stage immuno-oncology imaging company, today announces publication of its data in leading peer-reviewed medical radiology publication, The Journal of Nuclear Medicine (JNM). The paper entitled "First-in-human imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting[i]" reports the results from a first in-vivo clinical study to assess the safety, tolerability, and efficacy of ImaginAb’s lead product, CD8 tracer, 89Zr-Df-IAB22M2C, in visualizing the immune system.
ImaginAb, Inc., a clinical-stage immuno-oncology imaging company, is delighted to be part of ‘Immune-Image,’ the Innovative Medicines Initiative Joint Undertaking (IMI2 JU) project, launching today and which includes top academic institutions, companies, and a patient organization. The project has been awarded a €30 million grant for an initial period of five years to support research into novel tracer strategies for clinical imaging of immune cell dynamics.
ImaginAb celebrates the first screenings of Science Advisory Board member Dr. James Allison’s gripping documentary, Breakthrough, chronicling his discovery of the ground-breaking medicine that would become pivotal in the development of immunotherapy treatments for cancer.
ImaginAb Enrolls First Patient at the University of Alabama at Birmingham in On-going “Base Line/On Therapy” (BOT) Phase II Clinical Trial
ImaginAb Inc., a clinical-stage immuno-oncology imaging company, today announces it has enrolled its first patient for the Phase II clinical trial of its lead product CD8 tracer, 89Zr-Df-IAB22M2C, at the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham (UAB). This study is a collaboration between UAB’s Division of Hematology and Oncology and Division of Molecular Imaging and Therapeutics, reflecting UAB’s commitment to world-class research and clinical care.
ImaginAb Inc., a clinical-stage immuno-oncology imaging company, today announces that it is scheduled to attend and/or present at the following investor and scientific conferences in September and October 2019: Word Molecular Imaging Congress, ESMO Congress, Cavendish Global Conference: The 2019 Phoenix BioHealth Impact Forum, 2nd Annual Advances in Immuno-Oncology USA Congress, and Optimum 11th Annual Healthcare Investor Conference.
ImaginAb Inc., a clinical-stage immuno-oncology imaging company, announces it has initiated its Phase II clinical trial of its lead product, CD8 tracer 89Zr-Df-IAB22M2C, at Dana-Farber Cancer Institute in Boston, MA.